
Spartanburg Regional first in Upstate to treat enlarged prostate conditions with advanced Aquablation Therapy
Spartanburg Regional Healthcare System is the first healthcare system in Upstate South Carolina to offer an innovative procedure that treats men suffering from urinary problems due to enlarged prostate glands.
The HYDROS Aquablation Therapy device uses advanced, minimally invasive AI-powered treatment planning, advanced image guidance, robotic resection and a streamlined workflow for physicians to guide patients through exceptional treatment and recovery.
Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate that can cause urinary issues and is common in men over 45. The statistics are rising. BPH is the No. 1 reason men visit the urologist. Fifty percent of men 51-60 have BPH, and 90 percent of men 80-90 years old suffer from BPH. Advanced, minimally invasive treatment is actively working to reverse this trend.
Spartanburg Medical Center – Center for Urology – Spartanburg, led by physicians including Dr. Robert Strehlow, provides treatment, education and recovery services for a variety of conditions and illnesses including BPH.
“Our team is excited to offer this innovative treatment option for our patients,” Dr. Strehlow said. “While there are other surgical options that have had success, we believe Aquablation treats the most prostate tissue possible in a minimally invasive setting while preserving quality of life in terms of sexual function.”
Other methods of treatment can lead to men having to decide whether to compromise on symptom relief, recovery time or sexual function. This advanced water-based procedure minimizes this compromise by providing targeted treatment with robotic precision and efficiency.
Adding the HYDROS Aquablation Robotic System supports Spartanburg Regional’s commitment to clinical innovation and providing the latest, advanced treatment options.
To learn more about the HYDROS Robotic System, click here.
Click here to learn more about Spartanburg Regional’s commitment to clinical innovations.